BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Andreas Hochhaus, Sebastian Kreil, A. Corbin et al. · Leukemia · 2002 · 905 citations

Medicine, Molecular Biology, Molecular Genetics +11

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2003 · 771 citations · Full text

Medicine, Molecular Biology, Molecular Genetics +9

High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

Susan Branford, Zbigniew Rudzki, Sonya Walsh et al. · Blood · 2002 · 657 citations · Full text

Medicine, Hematology, Molecular Genetics +14

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Elias Jabbour, Hagop M. Kantarjian, Dan Jones et al. · Leukemia · 2006 · 387 citations

Medicine, Hematology, Oncology +11

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Giovanni Martinelli, Gianantonio Rosti et al. · Journal of Clinical Oncology · 2005 · 372 citations · Full text

Medicine, Hematology, Pharmacology +14